Unstable angina, non-Q wave myocardial infarction

Indication for Nadroparin

Population group: Suitable for both men and women, only adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

7,600-19,000 IU in 2 divided doses daily

Route of admnistration

Subcutaneous

Defined daily dose

7,600 - 19,000 [iU]

Dosage regimen

From 3,800 To 9,500 [iU] 2 time(s) per day every day

Active ingredient

Nadroparin is a low-molecular weight heparin. Nadroparin inhibits Factor Xa in particular and thrombin to a lesser extent. Inhibition is partially mediated via the plasma protease inhibitor antithrombin III. Nadroparin has less effect on platelet function and aggregation and only has a minor effect on primary haemostasis compared to heparin.

Read more about Nadroparin

Related medicines

Summary of Product Characteristics (SPC) : NADROPARIN SODIUM Solution for injection

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner